Nicholas A. Watkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicholas A. Watkins has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Willem H. Ouwehand
Department of Haematology, University of Cambridge, National Health Service Blood and Transplant, Cambridge, United Kingdom
5 shared publications- Arief Gusnanto
University of Leeds
3 shared publications - Iain C. Macaulay
Earlham Institute
3 shared publications C. Ellen van der Schoot
Department of Experimental Immunohaematology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
2 shared publicationsCordelia F. Langford
Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom
2 shared publicationsDaphne C. Thijssen-Timmer
Department of Experimental Immunohaematology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
2 shared publications
Latest Publications
- 1 June 2009
- Published by Elsevier in Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology
- Vol. 153 (2) , S160-S161
Characterisation of novel platelet surface thiol isomerase enzymes
- 1 June 2009
- Published by Elsevier in Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology
- Vol. 153 (2) , S160-S161
Characterisation of novel platelet surface thiol isomerase enzymes
- Open Access
- 7 May 2009
- Published by American Society of Hematology in Blood
- Vol. 113 (19) , e1-e9
A HaemAtlas: characterizing gene expression in differentiated human blood cells
Hematopoiesis is a carefully controlled process that is regulated by complex networks of transcription factors that are, in part, controlled by signals resulting from ligand binding to cell-surface receptors. To further understand hematopoiesis, we have compared gene expression profiles of human erythroblasts, megakaryocytes, B cells, cytotoxic and helper T cells, natural killer cells, granulocytes, and monocytes using whole genome microarrays. A bioinformatics analysis of these data was performed focusing on transcription factors, immunoglobulin superfamily members, and lineage-specific transcripts. We observed that the numbers of lineage-specific genes varies by 2 orders of magnitude, ranging from 5 for cytotoxic T cells to 878 for granulocytes. In addition, we have identified novel coexpression patterns for key transcription factors involved in hematopoiesis (eg, GATA3-GFI1 and GATA2-KLF1). This study represents the most comprehensive analysis of gene expression in hematopoietic cells to date and has identified genes that play key roles in lineage commitment and cell function. The data, which are freely accessible, will be invaluable for future studies on hematopoiesis and the role of specific genes and will also aid the understanding of the recent genome-wide association studies.
- 7 May 2009
- Published by American Society of Hematology in Blood
- Vol. 113 (19) , e1-e9
Open AccessA HaemAtlas: characterizing gene expression in differentiated human blood cells
Hematopoiesis is a carefully controlled process that is regulated by complex networks of transcription factors that are, in part, controlled by signals resulting from ligand binding to cell-surface receptors. To further understand hematopoiesis, we have compared gene expression profiles of human erythroblasts, megakaryocytes, B cells, cytotoxic and helper T cells, natural killer cells, granulocytes, and monocytes using whole genome microarrays. A bioinformatics analysis of these data was performed focusing on transcription factors, immunoglobulin superfamily members, and lineage-specific transcripts. We observed that the numbers of lineage-specific genes varies by 2 orders of magnitude, ranging from 5 for cytotoxic T cells to 878 for granulocytes. In addition, we have identified novel coexpression patterns for key transcription factors involved in hematopoiesis (eg, GATA3-GFI1 and GATA2-KLF1). This study represents the most comprehensive analysis of gene expression in hematopoietic cells to date and has identified genes that play key roles in lineage commitment and cell function. The data, which are freely accessible, will be invaluable for future studies on hematopoiesis and the role of specific genes and will also aid the understanding of the recent genome-wide association studies.
- Open Access
- 27 December 2006
- Published by American Society of Hematology in Blood
- Vol. 109 (8) , 3260-3269
Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins
To identify previously unknown platelet receptors we compared the transcriptomes of in vitro differentiated megakaryocytes (MKs) and erythroblasts (EBs). RNA was obtained from purified, biologically paired MK and EB cultures and compared using cDNA microarrays. Bioinformatical analysis of MK–up-regulated genes identified 151 transcripts encoding transmembrane domain-containing proteins. Although many of these were known platelet genes, a number of previously unidentified or poorly characterized transcripts were also detected. Many of these transcripts, including G6b, G6f, LRRC32, LAT2, and the G protein–coupled receptor SUCNR1, encode proteins with structural features or functions that suggest they may be involved in the modulation of platelet function. Immunoblotting on platelets confirmed the presence of the encoded proteins, and flow cytometric analysis confirmed the expression of G6b, G6f, and LRRC32 on the surface of platelets. Through comparative analysis of expression in platelets and other blood cells we demonstrated that G6b, G6f, and LRRC32 are restricted to the platelet lineage, whereas LAT2 and SUCNR1 were also detected in other blood cells. The identification of the succinate receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists.
- 27 December 2006
- Published by American Society of Hematology in Blood
- Vol. 109 (8) , 3260-3269
Open AccessComparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins
To identify previously unknown platelet receptors we compared the transcriptomes of in vitro differentiated megakaryocytes (MKs) and erythroblasts (EBs). RNA was obtained from purified, biologically paired MK and EB cultures and compared using cDNA microarrays. Bioinformatical analysis of MK–up-regulated genes identified 151 transcripts encoding transmembrane domain-containing proteins. Although many of these were known platelet genes, a number of previously unidentified or poorly characterized transcripts were also detected. Many of these transcripts, including G6b, G6f, LRRC32, LAT2, and the G protein–coupled receptor SUCNR1, encode proteins with structural features or functions that suggest they may be involved in the modulation of platelet function. Immunoblotting on platelets confirmed the presence of the encoded proteins, and flow cytometric analysis confirmed the expression of G6b, G6f, and LRRC32 on the surface of platelets. Through comparative analysis of expression in platelets and other blood cells we demonstrated that G6b, G6f, and LRRC32 are restricted to the platelet lineage, whereas LAT2 and SUCNR1 were also detected in other blood cells. The identification of the succinate receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists.
- 30 October 2006
- Published by Elsevier in Journal of Immunological Methods
- Vol. 316 (1-2) , 75-83
Production of calmodulin-tagged proteins in Drosophila Schneider S2 cells: A novel system for antigen production and phage antibody isolation
- 30 October 2006
- Published by Elsevier in Journal of Immunological Methods
- Vol. 316 (1-2) , 75-83
Production of calmodulin-tagged proteins in Drosophila Schneider S2 cells: A novel system for antigen production and phage antibody isolation
- 1 June 2006
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (6) , 1197-1205
Definition of novel GP6 polymorphisms and major difference in haplotype frequencies between populations by a combination of in‐depth exon resequencing and genotyping with tag single nucleotide polymorphisms
- 1 June 2006
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (6) , 1197-1205
Definition of novel GP6 polymorphisms and major difference in haplotype frequencies between populations by a combination of in‐depth exon resequencing and genotyping with tag single nucleotide polymorphisms
- Open Access
- 1 December 2005
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 115 (12) , 3370-3377
Platelet genomics and proteomics in human health and disease
Proteomic and genomic technologies provide powerful tools for characterizing the multitude of events that occur in the anucleate platelet. These technologies are beginning to define the complete platelet transcriptome and proteome as well as the protein-protein interactions critical for platelet function. The integration of these results provides the opportunity to identify those proteins involved in discrete facets of platelet function. Here we summarize the findings of platelet proteome and transcriptome studies and their application to diseases of platelet function.
- 1 December 2005
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 115 (12) , 3370-3377
Open AccessPlatelet genomics and proteomics in human health and disease
Proteomic and genomic technologies provide powerful tools for characterizing the multitude of events that occur in the anucleate platelet. These technologies are beginning to define the complete platelet transcriptome and proteome as well as the protein-protein interactions critical for platelet function. The integration of these results provides the opportunity to identify those proteins involved in discrete facets of platelet function. Here we summarize the findings of platelet proteome and transcriptome studies and their application to diseases of platelet function.
- 1 July 2004
- Published by Wiley in Vox Sanguinis
- Vol. 87 (s2) , 151-154
Monoclonal antibody therapies in transfusion medicine
- 1 July 2004
- Published by Wiley in Vox Sanguinis
- Vol. 87 (s2) , 151-154
Monoclonal antibody therapies in transfusion medicine
- 5 March 2004
- Published by Wiley in Tissue Antigens
- Vol. 63 (4) , 345-354
Molecular studies of anti‐HLA‐A2 using light‐chain shuffling: a structural model for HLA antibody binding
Human leukocyte antigen (HLA) A2 is one of the most immunodominant HLA antigens. Through a process of light‐chain variable domain (VL) shuffling, we analyzed the VL domains' role in anti‐HLA‐A2/A28‐binding site diversity. This was achieved by combining a VH3‐30‐encoded HLA‐A2/A28‐specific heavy‐chain variable domain with 104 non‐immune VL domains. Twelve HLA‐A2/A28‐specific antibodies were subsequently identified. VL gene analysis demonstrated an absence of Vλ domains and that all have VκI‐encoded light chains. The affinities correlated with the VκI gene present, with the seven highest affinity antibodies using Vκ domains encoded by the O18 gene segment. A 300‐fold difference in affinity was observed between the 12 antibodies, and homology modeling demonstrated a correlation between electrostatic surface potential of the antigen‐binding site and affinity for HLA. Overlap between the T‐cell receptor‐binding site and that of the antibodies was indicated by inhibition of cytotoxic T‐lymphocyte killing of peptide‐pulsed target cells. A model of antibody binding to HLA‐A2 suggested contact with both α helices of the HLA molecule, such that the antigen‐binding site spans the peptide‐binding groove. These data increase the understanding of antibody recognition of HLA and may facilitate the production of clonotypic antibodies with peptide‐specific binding.
- 5 March 2004
- Published by Wiley in Tissue Antigens
- Vol. 63 (4) , 345-354
Molecular studies of anti‐HLA‐A2 using light‐chain shuffling: a structural model for HLA antibody binding
Human leukocyte antigen (HLA) A2 is one of the most immunodominant HLA antigens. Through a process of light‐chain variable domain (VL) shuffling, we analyzed the VL domains' role in anti‐HLA‐A2/A28‐binding site diversity. This was achieved by combining a VH3‐30‐encoded HLA‐A2/A28‐specific heavy‐chain variable domain with 104 non‐immune VL domains. Twelve HLA‐A2/A28‐specific antibodies were subsequently identified. VL gene analysis demonstrated an absence of Vλ domains and that all have VκI‐encoded light chains. The affinities correlated with the VκI gene present, with the seven highest affinity antibodies using Vκ domains encoded by the O18 gene segment. A 300‐fold difference in affinity was observed between the 12 antibodies, and homology modeling demonstrated a correlation between electrostatic surface potential of the antigen‐binding site and affinity for HLA. Overlap between the T‐cell receptor‐binding site and that of the antibodies was indicated by inhibition of cytotoxic T‐lymphocyte killing of peptide‐pulsed target cells. A model of antibody binding to HLA‐A2 suggested contact with both α helices of the HLA molecule, such that the antigen‐binding site spans the peptide‐binding groove. These data increase the understanding of antibody recognition of HLA and may facilitate the production of clonotypic antibodies with peptide‐specific binding.
- 1 January 2000
- Published by Wiley
- Vol. 78 (2) , 72-79
Introduction to Antibody Engineering and Phage Display
The vertebrate immune system, capable of rapidly producing highly specific antibodies upon immunisation, has been used to produce murine monoclonal antibodies (mAbs) via immortalisation and isolation of antibody–secreting cells. These mAbs have had a profound impact in the fields of diagnostics and therapeutics. However, the therapeutic use of murine mAbs is complicated by their immunogenicity. To circumvent this immunogenicity, antibody engineering techniques which render murine mAbs more compatible with the human immune system have been devised. Over the last decade, the technique of antibody phage display, which facilitates the production of human mAbs, has been developed. This review serves as an introduction to antibody engineering, phage display and the development of antibody fragments into viable diagnostic and therapeutic reagents.
- 1 January 2000
- Published by Wiley
- Vol. 78 (2) , 72-79
Introduction to Antibody Engineering and Phage Display
The vertebrate immune system, capable of rapidly producing highly specific antibodies upon immunisation, has been used to produce murine monoclonal antibodies (mAbs) via immortalisation and isolation of antibody–secreting cells. These mAbs have had a profound impact in the fields of diagnostics and therapeutics. However, the therapeutic use of murine mAbs is complicated by their immunogenicity. To circumvent this immunogenicity, antibody engineering techniques which render murine mAbs more compatible with the human immune system have been devised. Over the last decade, the technique of antibody phage display, which facilitates the production of human mAbs, has been developed. This review serves as an introduction to antibody engineering, phage display and the development of antibody fragments into viable diagnostic and therapeutic reagents.